GlassScriptPhysician profile
Daffaney J Webster
NPI 1265106405
$1,866.33
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $481 · 2023: $689 · 2024: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.86 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $701.18 | 2022-2024 | Caplyta |
| Abbvie INC. | $465.20 | 2022-2024 | |
| Alkermes, INC. | $155.60 | 2023 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $102.20 | 2022-2024 | Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $91.26 | 2023-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $68.15 | 2022-2024 | Fanapt |
| Corium, LLC | $65.01 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $49.51 | 2022 | |
| Lundbeck LLC | $45.73 | 2022 | |
| Ironshore Pharmaceuticals INC. | $29.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $21.70 | 2024 | Uzedy |
| Neurocrine Biosciences, INC. | $19.56 | 2023 | Ingrezza |
| Tris Pharma INC | $18.20 | 2024 | Dyanavel Xr |
| Exact Sciences Corporation | $17.17 | 2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $16.86 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daffaney Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.